The limitation of relying upon upfront tumour BRCA1/2 testing to identify all possible pathogenic variants is that most local tumour NGS assays are not yet validated to detect whole gene/exon deletions or duplications [11,36,37], although Myriad’s myChoice® CDx does reliably detect these variants [19]. Here, BRCA1 is linked to neoplasm.